| Cat.No. | Name | Information |
|---|---|---|
| M3887 | SB225002 | SB225002 is a potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM and >150-fold selectivity over CXCR1 and four other 7-TMRs. |
| M5160 | Reparixin | Reparixin is a noncompetitive allosteric inhibitor of IL-8 (CXCL8) activation of CXCR1 and CXCR2 chemokine receptors with IC50 of 1 and 100 nM, respectively. |
| M1898 | Plerixafor (AMD3100) | Plerixafor (AMD3100) is a CXCR4 chemokine receptor antagonist. |
| M9286 | MSX-127 | MSX-127 (NSC-23026) is a CXCR4 receptor modulator. |
| M9275 | AZD-5069 | AZD-5069 is a potent CXCR2 chemokine receptor antagonist, and is claimed to be useful in the treatment of inflammatory diseases. |
| M9070 | AMG 487 | AMG 487 is a potent and selective antagonist of chemokine (C-X-C motif) receptor 3 (CXCR3) with IC50 values of 8nM and 8.2nM for I-IP-10 and I-ITAC, respectively. |
| M7261 | SB 265610 | SB 265610 is a potent CXCR2 antagonist. |
| M6271 | SRT3109 | SRT3109 is a CXCR2 ligand for use in the treatment of chemokine mediated diseases and conditions. |
| M6217 | AMD-070 | AMD-070 is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. |
| M5210 | GSK1325756 (Danirixin) | GSK1325756 (Danirixin) is a non-peptide, high affinity, selective and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8. |
| M5165 | MSX-122 | MSX-122 is a novel small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions (IC50 = 10 nM). |
| M4204 | Baohuoside-I | Baohuoside I is a flavonoid obtained from Epimedium Korean. As an inhibitor of CXCR4, Baohuoside I can inhibit the expression of CXCR4 and induce apoptosis, showing antitumor activity. |
| M3769 | Plerixafor 8HCl | Plerixafor 8HCl (AMD3100 8HCl) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. |
| M2381 | AMD3465 hexahydrobromide (AMD3465 ) | AMD3465 hexahydrobromide（AMD3465 ) is an effective CXCR4 antagonist that inhibits 12G5 mAb in SupT1 cells. The IC50 values of CXCL12AF647 and CXCR4 were 0.75 nM and 18 nM, respectively. AMD 3465 also effectively inhibited X4 HIV replication (IC50, 1-10 nM), but not R5 HIV replication. |
| M2161 | SCH527123 | SCH527123 is a novel, selective CXCR2 receptor antagonist with IC50 of 3 nM. |
| M2041 | WZ 811 | WZ811 is a highly competitive CXCR4 antagonist with oral activity. WZ811 effectively inhibited CXCR4/SDF-1 (also known as CXCL12) -mediated regulation of cAMP level (EC50=1.2 nM) and SDF-1-induced matrix glue invasion (EC50=5.2 nM) in cells. |
| M54418 | FC131 TFA | FC131 TFA is a CXCR4 antagonist, inhibits [125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM. |
| M54296 | CTCE-0214 | CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. |
| M53909 | TC14012 | TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. |
| M53208 | CXCR4 antagonist 4 | CXCR4 antagonist 4 is a potent, orally active CXCR4 antagonist (IC50=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC50=7 nM). |
| M53207 | Ac-Pro-Gly-Pro-OH | Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and can be used as CXCR2 agonist. |
| M53206 | SDF-1α (human) | SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. |
| M53205 | vMIP-II (1-21) | vMIP-II (1-21) is a CXCR4 antagonist. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
